Alzheimer's disease (AD) is one of the most common neurodegenerative disorders, and its prevalence is estimated to increase two-fold in industrialized countries and by four-fold in developing countries over the next 20 years[@b1]. AD is characterized by a loss in connectivity in several brain fields in particular including the hippocampus. For instance, the density of synapses was significantly decreased in the outer molecular layer of the hippocampal dentate gyrus in AD[@b2]. Notably, the hippocampus plays a key role in the neurodegenerative events occurring in AD, since changes in this field are closely associated with memory loss and cognitive impairment[@b3]. Despite recent progress in understanding the mechanism of AD, our knowledge of the molecular details regarding this disease is still incomplete.

Many previous studies of AD have focused on the CA1 and CA3 fields of the hippocampus in various species[@b4][@b5]. By contrast, our laboratory has focused on these hippocampal fields less studied in the context of AD pathology. Notably, the DG plays a major role in age-related memory impairment but relatively little is known about the molecular mechanisms responsible for this memory loss[@b6]. Furthermore, pathological changes in the DG, including granule cell loss and mossy fibre sprouting, are closely associated with status epilepticus[@b7]. Moreover, potential proteome-wide changes in the CA4 field of AD or their biological function remain unknown. In general, the lack of research on the DG and CA4 fields could in part be due to the lack of a clear distinction between the DG and CA4 in terms of their function and role in AD. This lack of clarity is why we specifically selected these fields from hippocampal tissues of AD patients and compared them to control samples.

Key initiating factors of AD include the accumulation of intraneuronal neurofibrillary tangles (NFTs) and the appearance of extracellular β-amyloid deposits[@b8][@b9]. One of the main histological findings in the brains of AD patients is the intracellular accumulation of NFTs[@b10][@b11]. Other histopathological features include the accumulation of extracellular senile plaques comprised of aggregated β-amyloid peptides. However, the molecular mechanisms associated with AD pathogenesis are not entirely understood. Moreover, some areas of the hippocampus are vulnerable to specific degenerative processes depending on their subfield and may differentially express proteins in specific stages of the disease. Intraneuronal neurofibrillary changes exhibit a characteristic pattern according to pathological stage of AD[@b12]. Therefore, in the current study, we focused on relatively early AD pathology, when accumulation of NFTs and neuropil threads are first detected in the CA4/DG[@b12] to elucidate mechanisms involved in the onset and development of AD. To accomplish this, we used hippocampal specimens staged at AD Braak -IV and AD Braak -V. Using the differentially-expressed proteins identified from the CA4/DG field, we also examined protein-protein interaction networks associated with the mechanisms of AD through a bioinformatics approach. An examination of the signalling interaction networks associated with AD can provide insights into the molecular events mediating AD pathology. In addition, it can provide identifying potential new diagnostic or prognostic biomarkers.

Most previous studies that aimed to identify biomarkers for AD diagnosis have predominantly employed positron emission tomography (PET) and magnetic resonance imaging (MRI) approaches[@b13]. However, new tools have now been developed which are highly more sensitive and specific and are able to detect biomarkers relevant to disease progression and the signalling pathways underlying AD. Thus, in the current study, we combined mass spectrometry-based proteomic analysis with label-free quantification for identification and quantification of proteins from AD and control samples. We dissected the CA4 and DG fields from human hippocampal tissues and used one-dimensional liquid chromatography-tandem mass spectrometry (LC-MS/MS) with subsequent database searches to identify peptides. Using this methodology, we identified previously unknown pathological mechanisms of AD. Additionally, the use of multiple high-throughput technologies enabled the detection of novel proteins and cellular signalling pathways associated with AD pathology. Among the proteins identified, we targeted five regulated proteins (MDH2, PCLO, TRRAP, YWHAZ, and MUC19 isoform 5) and cross-validated them by using western blot analyses, selective reaction monitoring (SRM), and matrix-assisted laser desorption/ionization (MALDI) mass spectrometry imaging (MSI). Thus, we combined leading proteomic technologies for use as a diagnostic tool for the identification novel AD biomarkers and candidate drug targets. Our results provide valuable clinical information and can be utilized as a novel platform for the early diagnosis of AD.

Results
=======

AD biomarker identification
---------------------------

To select meaningful proteins from total identified proteins in AD and control hippocampi, we performed a systematic data-mining strategy using an in-house protocol that involved four stages ([Fig. 1](#f1){ref-type="fig"}). A total of 5,784 proteins from AD and control hippocampal tissues were extensively profiled by high-resolution nanoLC/MS throughout stage 1 ([Fig. 1B](#f1){ref-type="fig"}). We identified 4,328 unique proteins from five AD hippocampus samples (2,085) and five control samples (2,243) ([Fig. 2A,B](#f2){ref-type="fig"}) using a minimum of one unique peptide and a protein FDR of ≤1%. Thereafter, we adopted a ratio cut-off of ≥1.8 and ≤0.56 and obtained 113 proteins (52 upregulated proteins and 61 downregulated proteins; stage 3) ([Table 1](#t1){ref-type="table"}) for the refinedverification set; stage 4 ([Fig. 1B](#f1){ref-type="fig"}). Recently, our institution[@b14] identified 5,971 proteins in AD hippocampal tissues by off-gel fractionation, and profiled these proteins by using a high-resolution mass spectrometer with collision-induced dissociation and electron transfer dissociation. [Fig. 2C](#f2){ref-type="fig"} shows the number of identified proteins in the CA4 and DG subfields and the entire hippocampus.

For our experiments, we selected only five hippocampi per group from the total specimens (Supplementary Information 1) since our criteria discriminated against each subfield of the hippocampus. For this purpose, we first investigated hippocampal histology to identify the individual subfields ([Fig. 3A](#f3){ref-type="fig"}) and coupled our observations to MALDI MSI.

Validation of proteomic profiling data
--------------------------------------

To the best of our knowledge, no previous studies have linked MUC19 isoform 5 with AD until now. Since there are no commercially available human MUC19 isoform 5 antibodies and the sequence of the MUC19 oligomeric protein (isoform 5) is slightly different from the full sequence of Muc19 protein (Supplementary Information 2). We used MALDI MSI and spectral counting to confirm that MUC19 isoform 5 was highly expressed specifically in AD hippocampal tissues in contrary to controls ([Fig. 3B, C](#f3){ref-type="fig"}). We next performed western blot analyses to confirm the expression levels of four proteins (MDH2, PCLO, TRRAP, and YWHAZ, with β-actin as control) identified in the CA4 and DG field of AD hippocampal tissues. Notably, higher levels of MDH2, PCLO, and TRRAP were observed in AD tissue than in control hippocampal tissue ([Fig. 4A](#f4){ref-type="fig"}); however, lower levels of YWHAZ were observed in control tissue. Furthermore, the western blot data for these proteins correlated well with the spectral counting data ([Fig. 4B](#f4){ref-type="fig"}). We also confirmed expression of MDH2 using SRM. As shown in [Fig. 4C](#f4){ref-type="fig"}, MDH2 expression was approximately two-fold higher in AD hippocampi than in control tissue.

We selected proteins to investigate according to differences in their potential function ([Fig. 5A](#f5){ref-type="fig"}). These unique classifications were composed of several categories including microtubule-based movement, cell-projection morphogenesis, neuronal development, glycolysis, neuronal-projection morphogenesis, and others as listed. Interestingly, proteins that were classified into the glycolysis category (PKM2, PGAM1, ENO3, PGK1, and MDH2) were found to be upregulated in AD tissue. By contrast, proteins classified as being involved in microtubule-based movement and chromatin organization tended to be downregulated in AD tissue ([Fig. 5A](#f5){ref-type="fig"}). A large proportion of the cellular components identified were cytoskeletal proteins ([Fig. 5B](#f5){ref-type="fig"}). In AD tissue, proteins classified as nucleotide binding and purine ribonucleotide binding proteins tended to be downregulated rather than upregulated by more than two-fold ([Fig. 5C](#f5){ref-type="fig"}).

Upstream signalling interactions of proteins differentially expressed in AD patients
------------------------------------------------------------------------------------

We used Ingenuity Pathway Analysis (IPA) to investigate the potential signalling interactions of the 113 proteins that were expressed more than 2-fold higher or lower in AD hippocampi than in control tissues. We determined the five most significantly annotated upstream regulators by using z-scores and p values ([Table 2](#t2){ref-type="table"}). These included two growth factors (IGF1, insulin-like growth factor 1; and BDNF, brain-derived neurotrophic factor), one kinase (ZAP-70 tyrosine-protein kinase), one transcriptional regulator (Myc proto-oncogene protein), and one biological drug (cyclosporin A). These factors markedly increased or decreased z-scores. We identified a signalling network representative of the relationship between the activation and/or inhibition of upstream regulators with downstream regulated proteins ([Fig. 6A](#f6){ref-type="fig"}). Through these tools, we also determined a protein interaction network for the potential role of our identified proteins in various neurological disorders ([Fig. 6B](#f6){ref-type="fig"}).

Discussion
==========

We employed nanoLC coupled with ESI-ion trap MS. Since nanoLC-based MS has the advantages of high spectral resolution and the ability to be used with a shotgun strategy, it can be utilized for identifying a large number of proteins in complex protein mixtures.

Using this approach, we identified 113 candidate molecules in tissue from patients with AD. Among these proteins, approximately 75% had a previously unknown relationship with AD; however, 60% of the 113 proteins had previously been reported to be associated directly or indirectly with the brain. To narrow down our investigation, we selected proteins that had previously been identified in neurological disorders, and validated our proteomic targets by employing western blot analysis and SRM, and MALDI MSI. SRM is particularly useful for validating candidate biomarker that require isotopically labelled standard but have no available antibodies[@b15]. Moreover, MALDI MSI has emerged as a powerful tool for molecular imaging of thin tissue sections and can provide information about the spatial distribution of proteins in tissue[@b16][@b17]. The AD-associated proteins that we chose to further investigate included PCLO, which is associated with major depressive disorder (MDD); MDH2, which has been shown to regulate oxidative stress; and TRRAP, which plays an important role, together with Fe65, in AD.

A recent genome-wide association study on MDD identified a specific relationship with a non-synonymous polymorphism (rs2522833) of a gene encoding the presynaptic protein, piccolo (PCLO)[@b18], which is localized to nerve terminals of both excitatory and inhibitory synapses in the CNS and influences Ca^2+^-dependent monoamine neurotransmitter release[@b19]. Bassoon and PCLO are critical regulators of presynaptic ubiquitination and degradation[@b20]. Surprisingly, in the current study we found that PCLO levels were higher and ubiquitin carboxyl-terminal hydrolase isozyme L1 (UCHL1) levels were lower in the hippocampus of AD in contrary to controls ([Fig. 4A](#f4){ref-type="fig"}). UCHL1 is related to mono-ubiquitin recycling and thereby, sustaining protein degradation by the ubiquitin-proteasome system (UPS). In addition, the down-regulation of UCHL1 in AD is determined by induction of the NF-kB pathway and an Aβ mediated up-regulation of BACE1, by interfering with its lysosomal degradation[@b21]. Our data suggest that PCLO and UCHL1 could be potential targets for new treatment development.

There were a number of protein changes that were not unexpected between AD and control tissue. One such protein, MDH, is involved in oxidative stress which is a process well known as one of the major causes of AD pathology[@b22]. During oxidative stress, MDH activity and MDH2 mRNA expression increased by 19% and 22%, respectively, in a mouse hippocampal cell line (HT22)[@b23]. According to our western blot data ([Fig. 4A](#f4){ref-type="fig"}), MDH2 was more highly expressed in AD hippocampal tissues than in controls. SRM verified that MDH2 expression was approximately two-fold greater in AD tissue ([Fig. 4C](#f4){ref-type="fig"}), and this difference between tissues was also consistently observed with spectral counting.

Another protein of interest, TRRAP, is a well-known cofactor of histone acetyltransferase, which binds to Tip60 to repair double-stranded DNA breaks[@b24]. TRRAP also plays a key role in the regulation of Fe65, which is a binding partner of the β-amyloid precursor protein, APP, to activate histone H4 acetylation at DNA strand breaks[@b25]. Therefore, it was not surprising that TRRAP was more highly expressed in AD hippocampi than in controls ([Fig. 4A](#f4){ref-type="fig"}).

The 14-3-3 zeta protein isoform 1 (YWHAZ) is associated with tau phosphorylation in NFTs, which is a characteristic neurohistological marker of AD[@b26][@b27]. In AD hippocampal tissues, low levels of YWHAZ have been previously reported[@b27]. Our current data, including the spectral counting and western blotting data, is consistent with this previous report in that we observed lower YWHAZ expression in AD hippocampal tissue than in control tissue ([Fig. 4A](#f4){ref-type="fig"}).

In contrast to the function of YWHAZ, UCHL1 was previously reported[@b28] to play an important role in preventing neurofibrillary tangle formation by de-ubiquitination of phosphorylated tau. Interestingly, UCHL1 expression was downregulated in patients with AD ([Table 1](#t1){ref-type="table"}) compared with that of the controls. We propose that the low levels of UCHL1 expression may have affected AD patients' ability to prevent NFT formation.

Another protein involved in AD pathology, ITPR1 (inositol 1,4,5-trisphosphate receptor, type 1), is well known as an important protein involved the regulation of Ca^2+^ homeostasis and apoptosis in AD. ITPR1 is localized to the endoplasmic reticulum and interacts with β-amyloid peptide; it is possible that this interaction could influence intracellular calcium homeostasis[@b29], induce inactivate eNOS, and ultimately lead to apoptosis. Our data indicated that ITPR1 was approximately three-fold higher in the AD hippocampus than in control tissues.

Levels of dihydropyrimidinase-related protein 2 (DPYSL2; CRMP2), E3 ubiquitin-protein ligase (HUWE1), and sodium/potassium-transporting ATPase subunit alpha-3 (ATP1A3) were significantly lower in AD samples compared with controls. DPYSL2 has been implicated in neuronal growth, polarity, and guidance as well as in AD[@b30]. Further, chromosomal microduplication or mutation of HUWE1 has been associated with mental retardation[@b31]. ATP1A3 is known to be a Na+/K+ transporter important in maintaining Na+/K+ gradients in neurons[@b32].

The neuron navigator protein family is also of interest. According to our results, neuron navigator 1 was upregulated whereas neuron navigator 2 and 3 were downregulated in AD tissue ([Table 1](#t1){ref-type="table"}). These proteins are regulators of axon guidance and serve as targets for miRNA. Neuron navigator 1 is a novel microtubule-associated protein, which is involved in neuronal migration[@b33], while neuron navigator 2 plays a key role in axonal elongation and formation. It provides stability to growing neurites[@b34]. Shioya *et al*.[@b35] recently reported that a lack of correlation between the mRNA and protein levels of neuron navigator 3. Interestingly, a recent study showed that neuron navigator 3 is involved in tumour suppression[@b36].

Notably, IGF1 modulates the hyperphosphorylation of tau through activation of kinases[@b37][@b38][@b39][@b40]. The cited study[@b39] reported that increased IGF1 levels in middle age are associated with a high risk of AD at an older age. In addition, hyper-activation of IGF1-receptor signalling is an important risk factor for AD[@b41]. We also identified four regulated proteins (dystrophin, glial fibrillary acidic protein \[GFAP\], myelin basic protein \[MBP\], and antigen KI-67 \[MKI67\]), which were highly expressed in AD tissue and were associated with IGF1 upstream regulation. This IGF1-associated signalling interaction could contribute to the pathogenesis of AD. Another growth factor protein identified was BDNF, which is associated with energy homeostasis[@b42] and plays a neuroprotective role in AD [@b43][@b44]. Furthermore, decreased BDNF mRNA and protein levels are observed in tauopathies and neurodegenerative disease[@b45]. Interestingly, our results suggest that Myc may inhibit the activation of BDNF-associated upstream regulators ([Fig. 6A](#f6){ref-type="fig"}). The Myc oncogene family of proteins are upregulated[@b46] and induce apoptosis[@b47] in AD. We found that seven downstream proteins (heat shock protein HSP 90-alpha \[HSP90AA1\], \[MBP\], \[MKI67\], phosphoglycerate mutase 1 \[PGAM1\], phosphoglycerate kinase 1 \[PGK1\], pyruvate kinase PKM, and ADP/ATP translocase 2 \[SLC25A5\]) were upregulated in AD tissue and were upstream regulators of Myc. According to our data, activation of Myc may inhibit BDNF, which is known to play a neuroprotective role in AD. Tyrosine-protein kinase ZAP-70 (ZAP70; SRK), which regulates the adaptive immune response, was one of the kinase proteins identified. Here, we identified four downstream proteins (HSP90AA1, ITPR1, E3 ubiquitin-protein ligase MYCBP2, and plectin \[PLEC\]) associated with the upstream regulator ZAP70. ITPR1 is particularly important for the activation of apoptosis pathways downstream from the ER via activation of various kinases[@b48][@b49][@b50] ([Fig. 6A](#f6){ref-type="fig"}). These data suggest that activated ZAP70 may induce neuronal apoptosis through calcium-induced T lymphocyte apoptosis and/or immune response pathways. We also identified an inhibitor of upstream regulation, cyclosporin A (CsA), which is a biologic drug. CsA is an immunosuppressive cyclic peptide that binds cyclophilin A[@b51]. In addition, CsA prevents neuronal death[@b52][@b53] and β-amyloid-induced late-phase long-term potentiation deficits[@b54]. These data suggest that CsA may be a potential therapeutic agent for the treatment of AD by negatively regulating downstream proteins (GFAP, HSP90AA1, ITPR1, and MDH2). A number of proteins were also associated with neurological disease pathways ([Fig. 6B](#f6){ref-type="fig"}).

When dealing with human tissues, many variables must be taken into account that could potentially influence study results including age, PMI, sex, and other factors. The post-mortem integrity of post-translational protein modifications is largely unknown; however, in an AD patient population, factors such as age, gender, and PMI, had no significant effect on neuronal nuclear diameter[@b55]. Additionally, rapid autopsy programs are not well established[@b56][@b57]. Even with these variables, human brain-based research is still required and will aid our understanding of disease pathology[@b58]. In particular, when considering recent findings related to pathological analyses of the CA4 and DG fields from patients with AD. Notably, our group was the first to provide a molecular study of the CA4 and DG subfields in AD[@b12].

AD is classically diagnosed by neuropsychological testing combined with neuroimaging. Both methods are non-invasive; however, both approaches are also not very sensitive. One recent addition to the approaches adopted to clinically diagnose this debilitating disease is the use of biomarkers, including β-amyloid and tau, measured in the cerebral spinal fluid[@b59][@b60]. More specificity was introduced with the use of PET and Pittsburgh compound B, which can identify amyloid deposits. With our approach, disease diagnosis can be further improved, since proteomic changes can now be observed at high resolution on a cellular level. Obviously, our method has the disadvantage of being invasive and can only be performed post-mortem, limiting most of our observations to the late stages of AD; however, we believe that this proteomic approach will be particularly useful for examining connectomics in AD in which amyloid-induced neurotoxicity induces a loss of connections between neurons, thereby initiating the neurodegenerative process. Consequently, the five putative AD biomarkers (MDH2, PCLO, TRRAP, YWHAZ, and MUC19) are not just potential biomarkers. Instead, together with the five upstream signalling factors (IGF1, BDNF, ZAP70, MYC, and cyclosporin A) they could help uncover the molecular mechanisms mediating AD or different neurodegenerative diseases.

Methods
=======

Ethics statement and collection of human tissues
------------------------------------------------

All experiments were approved by the local Ethic Committee in accordance with the Spanish and European legislation on this topic. Methods of collection for human brain tissues were performed in accordance with procedures that were approved by the Ethics Committee of the University of Barcelona.

Chemicals
---------

All chemicals were of the highest purity obtainable. Water, formic acid, trifluoroacetic acid (TFA), acetonitrile (ACN), and methanol were purchased from Biosolve B. V. (Valkenswaard, the Netherlands). Ammonium bicarbonate, ethanol (EtOH), α-cyano-4-hydroxycinnamic acid, aniline (ANI), sinapinic acid (SA), and 1,1,1,3,3,3-hexafluoro-2-propanol reagents for Toluidine blue staining were purchased from Sigma-Aldrich (Saint-Quentin Fallavier, France). Trypsin was purchased from Promega (Charbonnieres, France).

Human tissue
------------

Control and AD hippocampal specimens were acquired from the Barcelona Brain Bank in Spain. Control hippocampi were obtained from donors who had no known history of neurological or psychiatric disease. The inclusion criterion for AD tissue was a clinical diagnosis (AD-IV, AD-V). Once the tissue was received, it was immediately frozen and stored at --80 °C until further use. For this study, we used the following brain specimens: controls (age 55, 52, 63, 68, and 69 years with a post-mortem interval (PMI) of 9, 3, 6, 4, and 3 h, respectively), AD samples (age 79, 83, 75, 77, and 56 years, with a PMI of 18, 15, 11, 20, and 7 h, respectively) (Supplementary Information 1). Tissues were acquired and stored by the Barcelona Brain Bank, who also obtained informed consent and ethics committee approval.

Tissue sample preparation
-------------------------

Ten-micrometre sections were obtained using a cryostat CM1510S (Leica Microsystems, Nanterre, France) and mounted onto indium-tin oxide (ITO)-coated conductive glass slides (Bruker Daltonics, Bremen, Germany). Sections were then vacuum-dried in a desiccator for 10 min and placed in a series of 70% EtOH, 95% EtOH, and chloroform solutions for 30 s each with concomitant drying under vacuum for 5 min. Sections were then dried and stored under vacuum. After MALDI analysis, the matrix was removed from some sections by washing slides with 70% EtOH; these sections were then stained using toluidine blue.

Matrix deposition
-----------------

For matrix deposition, an ionic matrix solution containing 10 mg/mL of SA and one equivalent of ANI in ACN/0.1% TFA (7:3, v/v) was prepared. The matrix was deposited on human hippocampal tissue sections with an automatic ImagePrep sprayer (Bruker Daltonics, Bremen, Germany), which creates an aerosol by vibrational vaporization and provides high-resolution images. SA/ANI deposition was performed using a custom method composed of an initialization phase to deposit the first layer of matrix on the slide followed by phases enabling favourable co-crystallization of matrix crystals and analytes (by virtue of alternating cycles of partial and complete drying).

MALDI-TOF MSI
-------------

The MALDI matrix was applied using an ImagePrep device as described above. Protein imaging was then performed on an Ultraflex II MALDI-TOF/TOF instrument (Bruker Daltonics, Bremen, Germany) equipped with a smartbeam laser (Nd:YAG, 355 nm). Protein mass spectra were acquired in linear positive ion mode within a mass range of m/z 3,000--30,000. The distance between raster points was set to 80 μm with a total of 500 laser shots accumulated at a 200-Hz repetition rate for each pixel. Spectra were processed by baseline correction and smoothed using FlexAnalysis 3.2 software (Bruker Daltonics, Bremen, Germany). Image analysis and data visualization were performed with FlexImaging 2.1 software (Bruker Daltonics, Bremen, Germany). For statistical analysis, datasets obtained from FlexImaging were loaded into ClinProTools 2.2 software (Bruker Daltonics, Bremen, Germany) to conduct hierarchical clustering. Unsupervised clustering was selected with Euclidean as the distance method and Ward as the linkage method.

MALDI image normalization
-------------------------

Normalization of MALDI imaging data is not appropriate for single spectra, but instead requires the dataset as a whole. Here, we normalized data with the aim of equalizing the total ion count for all spectra to counter the effect of image 'hot spots'. One example of a hot spot occurring is when a large matrix crystal had been hit directly by the laser beam, resulting in higher spectrum intensity at this point. However, normalization has the disadvantage of artificially increasing the intensity of pure noise spectra. It is therefore possible to exclude noise spectra by defining a Y*mean*/Y*max* cutoff. Normalization was performed according to the following calculation:

y = y value at a point in the spectrumn = number of data points in the spectrumIf Y*mean* \< threshold factor × maximum value of the y-axis, then the spectrum will be normalized.

Histological staining
---------------------

For toluidine blue staining, tissue sections were removed from the SA/ANI matrix with 70% EtOH and dried; thereafter, sections were stained with toluidine blue for 1--2 min and washed in distilled water. After dehydration in a series of graded EtOH solutions, sections were placed in xylene, mounted, and examined by light microscopy[@b61].

Micro tissue extraction
-----------------------

Human brain tissue sections (20-μm thickness) were obtained using a cryostat CM1510S (Leica Microsystems, Nanterre, France) and mounted onto parafilm-covered slides. Micro-extraction was performed using microscopy to extract the CA4 and DG fields from AD and control hippocampal tissues.

NanoLC-ESI ion-trap MS and MS/MS
--------------------------------

After micro tissue extraction, analyses were performed on an ion-trap mass spectrometer (Esquire 3000 plus, Bucker Daltonics) equipped with a ESI ion source and on-line coupled to a nanoLC system. An injection of 0.5 μL of the digest was performed with a Switchos Autosampler (Dionex Corporation) and separation was performed on a C18 silica-bonded stationary phase (75 μm internal diameter, 150 mm long, 3 μm particle size, 100 Å pore size, Dionex). Samples were washed with 100% mobile phase A (95% water, 5% ACN, 0.1% formic acid) for 2 minutes at a flow rate of 10 μL/min. Peptides were then eluted using a linear gradient of 1%/minute mobile phase B (80% ACN, 20% water, 0.08% formic acid) for 70 minutes at a flow rate of 0.2 μL/min. The Esquire system was operated in a data-dependent MS/MS mode in which 1 MS full scan was followed by 1 MS/MS scan on the most-abundant peptide ion. Collision energy was set to 35%. Heated capillary temperature and electrospray voltage were 160 °C and 1.5 kV respectively[@b62].

Protein identification using label-free quantification and statistical analysis
-------------------------------------------------------------------------------

Raw MS data from patients with AD and controls were processed for protein identification using Mascot Daemon (v.2.3.2) with a peptide mass tolerance of 100 ppm and a fragment mass tolerance of ±0.8 Da at a false discovery rate (FDR) of 1% for both proteins and peptides. All peak lists were identified with the human International Protein Index (IPI) database (v3.87; containing 91,491 entries) with a decoy using the following parameters: enzyme: trypsin, missed cleavages: ≤2, fixed modification: carbamidomethyl (C), variable modifications: oxidation (M), and phosphorylation (S, T, Y). For relative protein quantification, the Mascot output file (csv format) was first imported into Microsoft Excel with additional filtering applied as follows: protein score ≥40, elimination of contaminants, and reversed sequences for each IPI name. A spectral index (SI) was calculated by summing all spectral counts using only unique peptides. Second, spectral indices from respective IPI names were normalized to the number of total counts estimating the relative amount of varying IPI names within a relative sample. Third, the average ratio of normalized SI was calculated between control tissue and AD tissue. Finally, a Student's t-test was performed for each IPI name (p \<0.05). To control the FDR, the resulting p values were adjusted for multiple testing according to the method of Benjamini and Hochberg[@b63] and compared with a significance level of alpha = 0.05. A protein was accepted as differentially expressed if it exhibited a ratio \>1.8 AD or control tissue and an adjusted p value \<0.05.

Gene annotation and upstream regulator analysis
-----------------------------------------------

Gene ontology annotation enrichment analysis was performed using the DAVID Bioinformatics Resource (v6.7) developed by NIAID, at the National Institutes of Health. Ingenuity Pathway Analysis (IPA; Ingenuity Systems, <http://www.ingenuity.com>) was used to functionally annotate genes implicated in disease and search for common upstream regulators.

Western blotting
----------------

For western blot analyses, protein extracts containing either 15 μg of AD or control lysate. Blots were then incubated overnight with primary antibodies \[rabbit polyclonal anti-TRRAP (1:1000, Abcam), rabbit polyclonal anti-YWHAZ (1:1000, AbFrontier), mouse monoclonal anti-PCLO (1:1000, Abcam), mouse monoclonal anti-MDH2 (1:1000, Abcam), and mouse monoclonal anti-β-actin (1:5000, Sigma)\] diluted in 5% skimmed milk powder in Tris-buffered saline (TBS) at 4 °C. Primary antibodies were incubated with peroxidase-conjugated anti-rabbit IgG (1:5000, Sigma) or peroxidase-conjugated anti-mouse I gG (1:5000, Sigma) secondary antibodies at RT. Antibody-reactive protein bands were visualized with an ECL detection reagent (GE Healthcare).

Optimization for peptide synthesis and SRM analysis in the MS instrument
------------------------------------------------------------------------

To perform SRM measurements, isotopically-labelled peptides were optimized with Optimizer software (MassHunter optimizer, version B. 0.3, Agilent, Palo Alto, CA, USA) to obtain the best analysis conditions for the triple quadrupole MS instrument. The optimization process selected fragment moieties from precursor ions and set the collision energy of fragment ions in each peptide. These samples were analysed with a nanoLC chip SRM/triple quadrupole MS, coupled with a 1200 Nano HPLC-chip microfluidic device (Agilent Technologies, Santa Clara, CA, USA). Samples (6 μL; 1.5 μg of protein) were injected via an autosampler and loaded onto the chip enrichment column, trapping 160 nL with a capillary pump, with a loading flow of 4 μL/min using a mobile phase composed of 0.1% formic acid in water. A separation column (Zorbax C18, 75 μm × 150 mm, 5 μm) was used for peptide separation, setting the analytical flow rate to 400 nL/min. Mobile phase A consisted of 97% water/3% ACN/0.1% formic acid, and mobile phase B consisted of 90% ACN/10% water/0.1% formic acid. The capillary pump flow rate was set at 4 μL/min for loading and washing the samples, using a 100% water/0.1% formic acid mobile phase. The LC gradient used increasing concentrations of B with the total run time equalling 60 min. ESI was accomplished by applying a spray voltage of 1840 V. MS instrument settings included a drying gas flow rate of 2.5 L/min, with a gas temperature of 325 °C, and an applied fragmentor voltage of 135 V(Supplementary Information 3).
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![Strategy for identifying putative biomarkers of AD.\
(**A**) Experimental scheme for analysis of regulated proteins from post-mortem AD tissues using mass spectrometry-based proteomic analysis with label-free quantification. (**B**) Protein prioritization scheme for the selection of candidate proteins for verification.](srep11138-f1){#f1}

![Venn diagrams summarizing proteins identified in human hippocampal tissue obtained from Alzheimer's disease and control patients.\
(**A**) Overlap of proteins identified in all five control hippocampi, (**B**) Overlap of proteins identified in all five AD hippocampi, (**C**) Overlap of proteins identified by comparison between the CA4 and DG subfields and the entire hippocampus.](srep11138-f2){#f2}

![(**A)** Annotated optical image of a hippocampal section obtained from an Alzheimer's disease patient stained with toluidine blue; Horn of Ammon (CA), dentate gryus (DG), and subiculum (S). (**B**) MUC19 isoform 5 is highly expressed in AD hippocampal tissues. MALDI imaging mass spectrometry (MSI) data (MUC19; m/z 11,135 ± 0.05%). (**C**) Spectral counting data for MUC19.](srep11138-f3){#f3}

![Validation of proteins identified by nanoLC coupled with ESI ion-trap MS.\
(**A**) Western blot analysis of MDH2, PCLO, TRRAP, and YWHAZ. (**B**) Spectral counting of PCLO, TRRAP, and YWHAZ. (**C**) Comparison of individual protein amounts with the fragmentation ratio (endogenous light peak area/heavy standard peak area) in AD and control tissues as assessed by SRM.](srep11138-f4){#f4}

![Analysis of regulated proteins using DAVID functional Gene Ontology.\
(**A**) Biological processes. (**B**) Cellular components. (**C**) Molecular functions (EASE score \> 1.3, p \< 0.05).](srep11138-f5){#f5}

![Features of proteomic signalling interactions.\
(**A**) Signalling network for the relationship between the activation and/or inhibition of upstream regulators with downstream regulated proteins (**B**) Interaction network for canonical neurological disease pathways including proteins that were up/downregulated in AD tissue.](srep11138-f6){#f6}

###### Upregulation and downregulation proteins list (Ratio ≥ 1.80 or p-value \< 0.05\*), SI = spectral index Asterisks indicate proteins with ratios that were significantly different from 1 (one-sample t-test, p \< 0.05\*).

           **IPI**            **GENE SYMBOL**   **Sequencecoverage (%)**   **No ofpeptide**   **AD(SI)**   **WT(SI)**   **AverageFold Change (AD/WT)**   **Adjustedp-value**     **IPI**     **GENESYMBOL**   **Sequencecoverage (%)**   **No ofpeptide**   **AD(SI)**   **WT(SI)**   **AverageFold Change (AD/WT)**   **Adjustedp-value**
  -------------------------- ----------------- -------------------------- ------------------ ------------ ------------ -------------------------------- --------------------- ------------- ---------------- -------------------------- ------------------ ------------ ------------ -------------------------------- ---------------------
   **Upregulaton proteins**                                                                                                                                                                                                                                                                                           
         IPI00470912             C2orf16\*                9.0                     12             7.53         0.00                   n.a                       0.00982         IPI01018212        PKM2                  22.2                    34             6.87         2.92                   2.35                      0.01708
         IPI00216864             PDZRN4\*                 9.5                     16             5.28         0.00                   n.a                       0.00731         IPI00333696      HEATR5B                 7.8                     21             5.72         2.43                   2.35                      0.01892
         IPI00876841             ZSWIM8 \*                4.6                     9              4.23         0.25                  16.72                      0.01489         IPI00069084       TRRAP                  2.3                     18             3.73         1.64                   2.28                      0.01892
         IPI00219446              PEBP1\*                 28.6                    10             3.30         0.24                  13.96                      0.00040         IPI00943735      ANKRD36                 6.3                     10             3.15         1.38                   2.28                      0.01892
         IPI00871535              SPTAN1                  3.0                     13             9.35         1.01                   9.24                      0.01892         IPI00642259        DST                   2.1                     29            12.91         5.72                   2.26                      0.01899
         IPI00964552             COL12A1\*                5.4                     28             6.88         0.97                   7.08                      0.00444         IPI00218474        ENO3                  14.7                    14             2.17         0.98                   2.21                      0.01892
         IPI00084828             STXBP1\*                 11.8                    9              3.78         0.57                   6.67                      0.01588         IPI00549725       PGAM1                  17.5                    9              3.78         1.74                   2.17                      0.01892
         IPI00413144             C15orf42                 6.2                     10             8.22         1.27                   6.48                      0.01766         IPI00291006        MDH2                  27.9                    25            11.18         5.21                   2.15                      0.01892
         IPI01014674              MUC19\*                 31.6                    11            10.22         1.89                   5.41                      0.01349         IPI00414123       CRMP1                  10.9                    6              0.99         0.46                   2.14                      0.02350
         IPI00954159             AHCTF1P1                 6.0                     20             8.06         1.52                   5.31                      0.01856         IPI00025363        GFAP                  61.1                   195            38.93        18.50                   2.10                      0.01856
         IPI00382470             HSP90AA1                 7.2                     8              5.18         1.01                   5.11                      0.01892         IPI00550232       XIRP2                  3.6                     18             6.33         3.09                   2.05                      0.01892
         IPI00169383               PGK1                   14.9                    4              3.22         0.67                   4.79                      0.01839         IPI00045512       HMCN1                  3.2                     30             6.90         3.39                   2.04                      0.01892
         IPI00879193               TTC28                  5.1                     13             6.89         1.46                   4.73                      0.01856         IPI00006091        DMD                   3.3                     9              5.55         2.73                   2.03                      0.01899
         IPI00007188              SLC25A5                 18.6                    5              1.00         0.22                   4.57                      0.01856         IPI00215715       CAMK2A                 13.5                    14             4.42         2.18                   2.03                      0.01892
         IPI00884904              AHNAK2                  3.4                     15            10.25         2.79                   3.67                      0.01892         IPI00930130       TUBB6                  48.0                   107             1.92         0.95                   2.02                      0.01892
         IPI01011955               MKI67                  7.2                     21             5.33         1.53                   3.49                      0.01892         IPI00419908       GPR179                 4.9                     9              4.24         2.10                   2.02                      0.02350
         IPI00218658               ITPR1                  5.8                     13             4.20         1.27                   3.31                      0.01856         IPI00171636        NAV1                  5.8                     10             3.76         1.92                   1.95                      0.01892
         IPI00328089             HIVEP3\*                 6.4                     17             8.16         2.53                   3.22                      0.01203         IPI01015973       MUC16                  8.6                    233             7.47         3.87                   1.93                      0.01892
         IPI00413173               MKI67                  3.4                     10            10.05         3.52                   2.85                      0.01856         IPI00004233       MKI67                  7.2                     21             9.39         4.93                   1.90                      0.02167
         IPI00411656              PCLO\*                  3.2                     26            16.37         5.81                   2.82                      0.01588         IPI00925013       MLL3\*                 12.5                    26             8.01         4.25                   1.89                      0.01689
         IPI00740909               ALMS1                  4.5                     21             6.37         2.28                   2.80                      0.01856         IPI00218621        SON                   7.6                     98             7.24         3.86                   1.87                      0.02078
         IPI00398002               PLEC                   4.1                     28             7.85         3.00                   2.61                      0.01892         IPI00329573      COL12A1                 7.2                     30             5.12         2.79                   1.84                      0.01932
         IPI00789624               PCLO                   6.7                     40            13.14         5.08                   2.59                      0.01839         IPI00797574       BOD1L                  5.9                     23            11.54         6.38                   1.81                      0.01856
         IPI00749231               GPR98                  3.5                     17             3.19         1.24                   2.58                      0.01892         IPI00021907        MBP                   32.2                    41             5.19         2.88                   1.80                      0.02579
         IPI00289776              MYCBP2                  4.2                     18            13.60         5.49                   2.48                      0.01892                                                                                                                                                           
         IPI00169307            ARHGAP21\*                6.3                     27             7.77         3.17                   2.45                      0.01489                                                                                                                                                           
         IPI00854820               PPRC1                  6.6                     14             2.86         1.18                   2.42                      0.01892                                                                                                                                                           
         IPI00215631               VCAN                   4.0                     21             4.29         1.79                   2.39                      0.01892                                                                                                                                                           
         IPI00102752               RBM15                  7.6                     20             4.99         8.89                   0.56                      0.01892         IPI00788168       MAST4                  3.5                     8              1.23         3.12                   0.39                      0.01892
         IPI00014845               DNAH8                  3.9                     29             2.63         4.73                   0.56                      0.01892         IPI00908811        CKB                   32.3                    26             1.05         2.69                   0.39                      0.01892
         IPI00217051               NAV3                   11.7                    33             8.65        15.58                   0.56                      0.01892         IPI00006451        NSF                   5.0                     4              1.01         2.58                   0.39                      0.01892
         IPI00044608               PLIN4                  17.2                    30             7.38        13.38                   0.55                      0.01892         IPI00031411        FAT1                  3.0                     17             2.66         7.08                   0.38                      0.01892
         IPI00854629               OBSCN                  2.3                     33             3.83         6.97                   0.55                      0.01892         IPI00983524        MBP                   58.6                    59             0.62         1.76                   0.35                      0.01856
         IPI00221325              RANBP2                  5.3                     14             3.98         7.24                   0.55                      0.02154         IPI00445401      HUWE1\*                 5.6                     27             2.39         6.99                   0.34                      0.01203
         IPI00868928              KIF26B                  5.5                     19             3.45         6.39                   0.54                      0.01892         IPI00257508      DPYSL2\*                23.3                    27             3.22        10.01                   0.32                      0.01203
         IPI01018628                UTY                   11.6                    24             5.10         9.47                   0.54                      0.01892         IPI00021263      YWHAZ\*                 17.0                    12             0.84         2.65                   0.32                      0.01489
         IPI00018352               UCHL1                  19.2                    10             1.77         3.30                   0.53                      0.01892         IPI00479743       POTEE                  14.1                    40             0.82         2.75                   0.30                      0.01892
         IPI00815697               NAV2                   12.0                    31             2.12         4.00                   0.53                      0.02549         IPI01019113        TUBB                  49.6                   155             0.23         0.79                   0.30                      0.01756
         IPI00003935             HIST2H2BE                19.0                    9              1.27         2.39                   0.53                      0.01892         IPI00006510       TUBB1                  11.7                    11             0.29         0.99                   0.30                      0.01892
         IPI00008161              ATP12A                  5.9                     12             0.77         1.46                   0.53                      0.01892         IPI01019105        UTY                   4.7                     10             1.29         4.57                   0.28                      0.01892
         IPI00018511              TUBB4Q                  11.7                    12             0.51         0.98                   0.52                      0.01977         IPI00478021      DNAH8\*                 4.0                     29             2.06         7.68                   0.27                      0.01676
         IPI00952742              SHANK2                  4.6                     14             2.05         4.00                   0.51                      0.01892         IPI00217002      KIAA2018                7.2                     11             1.48         5.65                   0.26                      0.01856
         IPI00297593               USP34                  4.0                     25             3.75         7.30                   0.51                      0.01892         IPI00853390      GPR112\*                5.8                     34             1.84         7.91                   0.23                      0.00982
         IPI00306457               FNDC1                  9.4                     10             2.74         5.42                   0.51                      0.01892         IPI00443415       MCC\*                  5.5                     9              0.99         4.32                   0.23                      0.01203
         IPI00019848               HCFC1                  7.5                     15             3.51         6.95                   0.51                      0.02078         IPI00956686      ATXN7\*                 15.6                    11             0.88         4.54                   0.19                      0.01203
         IPI00914628               USP24                  4.5                     9              1.76         3.48                   0.50                      0.02135         IPI00157790      KIAA0368                4.2                     7              0.99         5.17                   0.19                      0.01856
         IPI00026320               UBR5                   5.1                     15             6.07        12.42                   0.49                      0.01892         IPI00220717      RBM15\*                 7.6                     20             1.03         5.64                   0.18                      0.00731
         IPI00215877                APC                   7.6                     41             3.85         7.89                   0.49                      0.01892         IPI00795015       SACS\*                 1.9                     15             0.99         5.78                   0.17                      0.00731
         IPI00946001              ONECUT2                 26.8                    15             3.48         7.17                   0.49                      0.01891         IPI00738216     KIAA0947\*               7.1                     15             0.62         3.82                   0.16                      0.01203
         IPI00298994               TLN1                   6.9                     18             4.76         9.93                   0.48                      0.01856         IPI00642705      ARID1A\*                7.7                     25             1.33         8.27                   0.16                      0.00731
         IPI00914890               MAST4                  3.3                     8              1.17         2.47                   0.47                      0.02154         IPI01014270        APOB                  4.6                     21             1.33         9.55                   0.14                      0.01856
         IPI00788188              DYNC2H1                 5.4                     24             2.83         6.05                   0.47                      0.01892         IPI00740545      POTEI\*                 11.2                    26             0.21         1.54                   0.14                      0.00507
         IPI00007750              TUBA4A                  37.4                    56             0.55         1.19                   0.46                      0.01856         IPI00790327      ATP1A3\*                8.7                     27             0.40         4.10                   0.10                      0.01489
         IPI00026272             HIST1H2AE                21.8                    6              0.76         1.67                   0.46                      0.01892         IPI00879810       SPTAN1                 5.3                     18             1.00        10.50                   0.10                      0.01892
         IPI00985241                MBP                   67.5                    59             1.00         2.21                   0.45                      0.01892         IPI00917728       NEB\*                  3.7                     58             0.80         9.19                   0.09                      0.00549
         IPI00215628               VCAN                   5.5                     9              1.17         2.75                   0.43                      0.02109         IPI00871227      HMCN1\*                 3.1                     15             0.29         4.56                   0.06                      0.01203
         IPI00643465               TACC2                  3.2                     7              1.17         2.76                   0.42                      0.01892         IPI00386035       FLG\*                  11.7                    21             0.00         6.61                   n.a                       0.00731
         IPI00179298              HUWE1\*                 5.6                     43             4.55        10.74                   0.42                      0.01708         IPI00012645      SPTBN2\*                5.9                     10             0.00         6.66                   n.a                       0.00741
         IPI00847978               FAT3                   1.0                     13             2.56         6.06                   0.42                      0.02078                                                                                                                                                           

###### Annotated upstream regulators listed according to z-scores and p values.

   **Upstream Regulator**      **Molecule Type**      **Activation z-score**   **p-value**     **Target molecules in regulated proteins**
  ------------------------ ------------------------- ------------------------ ------------- -------------------------------------------------
           ZAP70                    Kinase                    2.000             4.12E--06             HSP90AA1, ITPR1, MYCBP2, PLEC
            IGF1                 Growth factor                1.970             6.92E--03                 DMD,GFAP, MBP, MKI67
            BDNF                 Growth factor                1.953             8.33E--04              GFAP, HSP90AA1, ITPR1, MBP
            MYC             Transcription regulator           1.865             2.49E--03    HSP90AA1, MBP, MKI67, PGAM1, PGK1, PKM, SLC25A5
       Cyclosporin A             Biologic drug                −1.982            7.61E--03              GFAP, HSP90AA1, ITPR1, MDH2

[^1]: These authors contributed equally to this work.
